Breast Cancer (Triple-Negative/Basal)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    PIK3CA Mutation  8 • Higher prevalence in metaplastic cancers ~40% (40,41)
    PTEN Mutation/loss 35 Temsirolimus (mTOR inhibitor):
    • Phase 1, with bevacizumab and liposomal doxorubicin: RR 32% in metaplastic (40)
    BRCA1/2 Mutation (germ line)  5 Olaparib (PARP inhibitor) (FDA approved):
    • Phase 3: PFS 7.0 vs. 4.2 mo for standard therapy in germline BRCA1/2. RR 59.9% vs. 28.8% (42)
    • Phase 2: RR 20% vs. 9.5% with prior platinum (43)
    Carboplatin:
    • Phase 3: RR 68% vs. 28% in non-BRCA
    Other topics in Targets by Organ Site